GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » E10

Natco Pharma (BOM:524816) E10 : ₹35.84 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Natco Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was ₹21.560. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹35.84 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Natco Pharma's average E10 Growth Rate was 28.20% per year. During the past 3 years, the average E10 Growth Rate was 16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Natco Pharma was 16.60% per year. The lowest was 8.90% per year. And the median was 12.75% per year.

As of today (2024-06-10), Natco Pharma's current stock price is ₹1082.15. Natco Pharma's E10 for the quarter that ended in Mar. 2024 was ₹35.84. Natco Pharma's Shiller PE Ratio of today is 30.19.

During the past 13 years, the highest Shiller PE Ratio of Natco Pharma was 50.70. The lowest was 19.95. And the median was 29.93.


Natco Pharma E10 Historical Data

The historical data trend for Natco Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma E10 Chart

Natco Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.66 22.59 23.44 27.96 35.84

Natco Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.96 30.70 32.72 33.91 35.84

Competitive Comparison of Natco Pharma's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Shiller PE Ratio falls into.



Natco Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Natco Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=21.56/153.0345*153.0345
=21.560

Current CPI (Mar. 2024) = 153.0345.

Natco Pharma Quarterly Data

per share eps CPI Adj_EPS
201406 2.024 94.103 3.292
201409 1.958 96.780 3.096
201412 0.870 96.780 1.376
201503 3.280 97.163 5.166
201506 1.700 99.841 2.606
201509 1.810 101.753 2.722
201512 2.130 102.901 3.168
201603 3.850 102.518 5.747
201606 2.730 105.961 3.943
201609 3.780 105.961 5.459
201612 11.160 105.196 16.235
201703 10.090 105.196 14.678
201706 5.580 107.109 7.973
201709 4.820 109.021 6.766
201712 12.250 109.404 17.135
201803 16.210 109.786 22.596
201806 9.820 111.317 13.500
201809 9.860 115.142 13.105
201812 8.673 115.142 11.527
201903 6.610 118.202 8.558
201906 7.850 120.880 9.938
201909 6.530 123.175 8.113
201912 5.730 126.235 6.946
202003 5.150 124.705 6.320
202006 6.730 127.000 8.110
202009 11.090 130.118 13.043
202012 3.430 130.889 4.010
202103 2.900 131.771 3.368
202106 4.110 134.084 4.691
202109 3.570 135.847 4.022
202112 4.400 138.161 4.874
202203 -2.770 138.822 -3.054
202206 17.550 142.347 18.868
202209 3.110 144.661 3.290
202212 3.410 145.763 3.580
202303 15.100 146.865 15.734
202306 23.260 150.280 23.686
202309 20.600 151.492 20.810
202312 11.880 152.924 11.889
202403 21.560 153.035 21.560

Add all the adjusted EPS together and divide 10 will get our e10.


Natco Pharma  (BOM:524816) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Natco Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1082.15/35.84
=30.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Natco Pharma was 50.70. The lowest was 19.95. And the median was 29.93.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Natco Pharma E10 Related Terms

Thank you for viewing the detailed overview of Natco Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Natco Pharma (BOM:524816) Business Description

Traded in Other Exchanges
Address
Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines